You are here: Home 
Categories Investigative Urology
Categories Investigative Urology Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models - Abstract
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models - Abstract
Published on 17 August 2012
Although androgen ablation therapy is the foundation of current prostate cancer treatment, most patients ultimately develop castration-resistant disease.
To read more, a FREE Urotoday registration is required. Click here to register or login above.To read UIJ content, a separate subscription is required.
Tags: